Relationship between frailty and lower urinary tract symptoms among community-dwelling adults
- PMID: 31642610
- DOI: 10.1111/luts.12292
Relationship between frailty and lower urinary tract symptoms among community-dwelling adults
Abstract
Objectives: To evaluate the relationship between frailty and lower urinary tract symptoms (LUTS), the association of frailty and LUTS remains unclear.
Methods: This cross-sectional study investigated LUTS and frailty in 710 individuals (249 men and 461 women, aged ≥60 years) who participated in the Iwaki Health Promotion Project between 2014 and 2015 in Hirosaki, Japan. Parameters of frailty were compared for individuals with mild and moderate to severe symptoms of LUTS. The International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) were used to evaluate LUTS. Frailty was evaluated by the frailty phenotype (FP), modified frailty index (mFI), and frailty discriminant score (FDS). The influence of frailty on LUTS was investigated by multivariate logistic regression analyses.
Results: Frailty parameters of age, renal function, and lower physical activity were significantly associated with severity of IPSS and OABSS. FP and mFI were significantly associated with severity of OABSS and IPSS, respectively. The FDS was significantly associated with severity of IPSS and OABSS. FP, mFI, and FDS were significantly associated with severity of nocturia. Multivariate logistic regression analyses revealed that FDS was independently associated with the severity of IPSS, OABSS, and nocturia, whereas FP and mFI were significantly associated with the severity of nocturia alone.
Conclusions: Individuals with LUTS are potentially frailer than those without LUTS. Although the influence of frailty on LUTS is different depending on the measurement tool, attention for frailty is necessary for subjects with LUTS.
Keywords: IPSS; Nocturia; frailty; lower urinary tract symptoms.
© 2019 John Wiley & Sons Australia, Ltd.
References
REFERENCES
-
- Yamanishi T, Asakura H, Seki N, Tokunaga S. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, open-label, controlled trial (DIrecT Study). Int J Urol. 2017;24(7):525-531.
-
- Fukumoto K, Nagai A, Hara R, Fujii T, Miyaji Y. Tadalafil for male lower urinary tract symptoms improves endothelial function. Int J Urol. 2017;24(3):206-210.
-
- Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol. 2017;24(10):716-729.
-
- Takeda M, Yokoyama O, Yoshida M, et al. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized, placebo-controlled, cross-over study. Int J Urol. 2017;24(7):539-547.
-
- Matsumoto T, Hatakeyama S, Imai A, et al. Relationship between oxidative stress and lower urinary tract symptoms: results from a community health survey in Japan. BJU Int. 2019;123(5):877-884.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
